Demonstrating its continued interest in antibody-drug conjugate (ADC) therapeutics, Amgen has agreed to pay up to US$2 B for exclusive access to Synaffix's ADC technology. The deal, which is currently for one undisclosed therapeutic, involves technology platforms GlycoConnect™, HydraSpace™ and select toxSYN™ linker-payloads; Amgen also has the opportunity to develop an additional four therapeutics. The agreement marks Synaffix's twelfth out-licensing agreement as pharmaceutical firms demonstrate increasing interest in the potential of its ADC technology platforms for cancer treatments.